Viemed Healthcare, Inc. (VMD) Stock Price & Analysis
Viemed Healthcare, Inc. (VMD) rose 0.78% to USD 9.08 as of September 8, 2026 at 10:52 UTC, according to Nexqual real-time market data.
VMD last closed at USD 9.01; the session ranged USD 8.95–9.13 on volume of 185,583 shares. Market capitalization is $345.84M, with a 52-week range of USD 6.05–12.61 (NCM). Source: Nexqual, September 8, 2026 at 10:52 UTC.
Key Statistics (as of September 8, 2026 at 10:52 UTC)
| Price | USD 9.08 |
|---|---|
| Change | ▲ 0.78% (up) |
| Previous Close | USD 9.01 |
| Open | USD 8.97 |
| Day Range | USD 8.95 – 9.13 |
| 52-Week Range | USD 6.05 – 12.61 |
| Volume | 185,583 shares |
| Market Cap | $345.84M |
| Exchange | NCM |
Technical Analysis (VMD)
Nexqual's technical model rates VMD "SELL" based on 1 bullish and 4 bearish signals across 128 daily candles, as of September 8, 2026 at 10:52 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 36.92 (neutral) |
| vs SMA50 | Below (USD 10.59) |
| MACD | -0.42 (negative) |
Analyst Ratings (VMD)
Wall Street analysts rate VMD "Buy" based on 2 analysts, with a mean price target of USD 12.5 (range USD 11–14), per Nexqual as of September 8, 2026 at 10:52 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 2 |
| Mean Target | USD 12.5 |
| High Target | USD 14 |
| Low Target | USD 11 |
| Buy / Hold / Sell | 1 / 1 / 0 |
Earnings (VMD)
| Next Earnings Date | 2026-11-04 |
|---|---|
| Revenue Estimate | $80.78M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 0.07 vs est 0.1 ▼ miss |
| 2026-03-31 | USD 0.06 vs est 0.09 ▼ miss |
| 2025-12-31 | USD 0.14 vs est 0.13 ▲ beat |
| 2025-09-30 | USD 0.09 vs est 0.09 ▲ beat |
Source: Nexqual, September 8, 2026 at 10:52 UTC.
Financials & Fundamentals (VMD)
| Total Revenue | $301.61M |
|---|---|
| Revenue Growth (YoY) | +23.90% |
| Gross Margin | +57.47% |
| Operating Margin | +6.48% |
| Profit Margin | +4.81% |
| ROE | +10.45% |
| Debt / Equity | 7.95 |
| Current Ratio | 1.13 |
| Total Cash | $10.68M |
| Total Debt | $11.60M |
| Free Cash Flow | $28.28M |
Source: Nexqual, September 8, 2026 at 10:52 UTC.
Financial Health Score (VMD)
Nexqual rates Viemed Healthcare, Inc.'s overall financial health "Solid" across five dimensions, as of September 8, 2026 at 10:52 UTC.
| Growth | Strong — Revenue +21% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 57%, operating 6% |
| Balance Sheet | Strong — $11M cash vs $12M debt |
| Cash Flow | Solid — FCF $28M, 10% margin |
| Efficiency | Mixed — ROE 10%, ROA 8.2% |
Ownership (VMD)
| Insider Ownership | +13.93% |
|---|---|
| Institutional Ownership | +71.00% |
| Shares Outstanding | 38.09M |
| Float | 30.64M |
| Short % of Float | +2.40% |
Source: Nexqual, September 8, 2026 at 10:52 UTC.
Leadership (VMD)
Viemed Healthcare, Inc. is led by Casey Hoyt (age 48), CEO & Director, per Nexqual as of September 8, 2026 at 10:52 UTC.
| CEO & Director | Casey Hoyt (age 48) |
|---|---|
| President | Michael B. Moore CRT (age 48) |
| Chief Financial Officer | Trae Paul Fitzgerald (age 37) |
| COO & Director | William Todd Zehnder (age 50) |
| Chief Medical Officer & Director | William Dana Frazier (age 67) |
Major Backers & Investors (VMD)
Notable institutional backers of Viemed Healthcare, Inc. include Forager Capital Management, LLC, Goldman Sachs, Ameriprise Financial, Inc., according to Nexqual as of September 8, 2026 at 10:52 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Forager Capital Management, LLC | 5.62% |
| Goldman Sachs | 3.75% |
| Ameriprise Financial, Inc. | 2.64% |
| Arrowstreet Capital, Limited Partnership | 2.06% |
| Nantahala Capital Management, LLC | 1.66% |
| PanAgora Asset Management, Inc. | 1.41% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 16.96% |
| Vanguard Group | 7.3% |
| Geode Capital | 2.56% |
| State Street | 2% |
Source: Nexqual, September 8, 2026 at 10:52 UTC.
From Viemed Healthcare, Inc.'s Latest SEC 10-K Filing (filed 2026-03-04)
Key Strengths & Strategy (as disclosed to the SEC)
- Viemed Healthcare, Inc., through its subsidiaries, provides home medical equipment (HME) and post-acute respiratory healthcare services in the United States.
- The company provides respiratory disease management solutions, including treatment of chronic obstructive pulmonary disease (COPD), which include non-invasive ventilation, percussion vests, and other therapies; and invasive and non-invasive ventilation and related equipment and supplies to patients suffering from COPD.
- It also sells and rents HME devices, such as non-invasive and invasive ventilators, positive airway pressure (PAP) machines, durable medical equipment, percussion vests, oxygen concentrators, and other medical equipment.
- In addition, the company provides neuromuscular care and oxygen therapy services; and sleep apnea management which provides sleep solutions and/or equipment, such as PAP, automatic continuous positive airway pressure, and bi-level positive airway pressure machines.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CLGN | CollPlant Biotechnologies Ltd. | USD 3.55 | ▲ 3.5% |
| SIBN | SI-BONE, Inc. | USD 18.5 | ▼ 3.44% |
| FKWL | Franklin Wireless Corp. | USD 2.45 | ▼ 0.23% |
| VREX | Varex Imaging Corporation | USD 18.51 | ▲ 0.22% |
| INFU | InfuSystems Holdings, Inc. | USD 12.24 | ▲ 0.82% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 10:52 UTC. This page is informational and not investment advice.